AI Signal & Stock Analysis · Weak ↓
As of Aug 14 2026, 1:04 PM, AkshayaAI's signal for ALNY is Weak ↓; the stock is at $227.79 (+0.29% today); neutral (RSI 40); technical trend is down-trend; news sentiment is positive.
Data as of Aug 14 2026, 1:04 PM. Informational analytics only — not investment advice.
| AI signal (Strength) | Weak ↓ |
|---|---|
| Price | $227.79 |
| Change today | +0.29% |
| RSI (14) | 39.54 |
| Relative volume | 0.61 |
| Composite (RMTPGV) score | 🔒 members |
| Market cap | $30.5B |
| Forward P/E | 22.44 |
| 52-week high | -54.1% away |
| 52-week low | +15.1% above |
| Technical trend | Down-trend (since 2024-01-26) |
| News sentiment | Positive |
| Sector | Healthcare-Biotech |
| Next earnings | 7/30/2026 8:30:00 AM |
As of Aug 14 2026, 1:04 PM, AkshayaAI assigns ALNY (Alnylam Pharmaceuticals Inc) a Weak signal. The composite (RMTPGV) score and full factor breakdown are available to signed-in members.
ALNY's RSI is neutral (RSI 40). A reading above 70 is typically considered overbought and below 30 oversold.
ALNY is trading about 54% below its 52-week high and 15% above its 52-week low as of Aug 14 2026, 1:04 PM.
ALNY's next earnings date is 7/30/2026 8:30:00 AM.
ALNY is classified under Healthcare-Biotech in AkshayaAI's taxonomy.
AkshayaAI provides AI-generated, informational stock analytics for US and India markets. This is not personalized investment advice. Figures are as of Aug 14 2026, 1:04 PM and may not reflect real-time prices. Always do your own research.
Instant, data-backed answers — free to try.